Seres Therapeutics
MCRB
#10246
Rank
ยฃ2.42 M
Marketcap
ยฃ0.28
Share price
1.11%
Change (1 day)
-61.36%
Change (1 year)

P/E ratio for Seres Therapeutics (MCRB)

P/E ratio as of April 2025 (TTM): -0.3340

According to Seres Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.334018. At the end of 2022 the company had a P/E ratio of -2.39.

P/E ratio history for Seres Therapeutics from 2015 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-2.39-79.03%
2021-11.4-48.3%
2020-22.1738.1%
2019-2.6341.58%
2018-1.86-59.46%
2017-4.596.13%
2016-4.32-68.59%
2015-13.8

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-4.95 1,382.94%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
-7.50 2,145.01%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.